Trump Nominates Marty Makary to Lead FDA; $1.5 Billion Sesamecare's Weight-Loss Drug Role in Focus

Nov 24, 2024, 09:39 PM

Marty Makary, a member of the board of directors of a $1.5 billion pharmaceutical company, has been officially nominated by President Trump to head the FDA. Makary is also the Chief Medical Officer for Sesamecare, a telehealth company that promotes compounded semaglutide, a weight-loss drug. His nomination intersects with obesity policy, raising concerns about the revolving door between industry and government. If confirmed as FDA commissioner, Makary would lead the FDA as it deals with high-stakes policy issues that could impact Sesamecare's business.